13C-Spirulina Gastric Emptying Breath Test (GEBT)
Advanced Breath Diagnostics · Decision date Apr 24, 2026
What did the FDA approve?
FDA records P110015/S012 as a supplement to PMA P110015, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Apr 24, 2026.
FDA approval order statement
approval for a manufacturing site located at Spirulina Production Facility, 318 Seaboard Lane, Suite 313, Franklin, TN 37067, USA, for packaging of the 13C-Spirulina/Egg Mix, finished device assembly and distribution operations of the 13C-Spirulina GEBT kit.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Clinical Chemistry
- Decision date
- Apr 24, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P110015/S012
- Regulatory pathway
- PMA supplement
- Applicant
- Advanced Breath Diagnostics
- Product code
- PGE
- Decision code
- APPR
- Decision date
- Apr 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Gastric Emptying Breath Test.
- Applicant
- Advanced Breath Diagnostics
- Product code
- PGE
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P110015/S011 · Related supplement
13C-Gastric Emptying Breath Test (GEBT), 13C-Spirulina Gastric Emptying Breath Test (GEBT), 13C-GEBT
P110015/S012 received
Application receipt date recorded by FDA.
P110015/S012 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P110015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Advanced Breath Diagnostics | PMA supplement | Jul 21, 2025 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Advanced Breath Diagnostics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 105 Westpark Dr. Suite 150, Brentwood, TN, 37027
Sources and methodology
- Original FDA record: P110015/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records